CASE REPORT

Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 1; peer review: 1 approved, 1 approved with reservations]

Georgios Nikolakis^{1,2}, Katja Kreibich¹, Aristeidis Vaiopoulos^{1,2}, Katarzyna Kaleta³, Joud Talas¹, Markus Becker¹, Christos C. Zouboulis^{1,2}

¹Departments of Dermatology, Venereology, Allergology and Immunology, Dessau Medical Center, Brandenburg Medical School Theodor Fontane and Faculty of Health Sciences Brandenburg, Dessau, 06847, Germany

²European Hidradenitis Suppurativa Foundation e.V., Dessau, 06847, Germany

³Department of Dermatology, Jagiellonian University Medical College, Krakow, 31-008, Poland

V1 First published: 13 May 2021, 10:381
<https://doi.org/10.12688/f1000research.52100.1>
 Latest published: 16 Jul 2021, 10:381
<https://doi.org/10.12688/f1000research.52100.2>

Abstract

Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic arthritis (PAPASH), spondyloarthritis (PASS) and psoriatic arthritis (PsaPASH) and are categorized in the autoinflammatory syndromes. anti-TNF- α and anti-IL-1 α blockade are between the therapeutic approaches that improve skin symptoms and prevent permanent osteoarticular damage. This case report refers to the successful treatment of a mixed phenotype of the aforementioned symptoms using the IL-17A inhibitor secukinumab after initial treatment with adalimumab. The therapy improved both cutaneous and reported osteoarticular symptoms. Different approaches for these recalcitrant HS syndromes are essential in order to achieve long-term remission for those patients.

Keywords

PASH, PAPASH, PASS, "hidradenitis suppurativa", SAPHO, PAPA, "acne inversa", hidradenitis, secukinumab, syndrome, arthritis, autoinflammatory, pustulosis

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
16 Jul 2021
version 1
13 May 2021

1. **Mathilde Daxhelet** , Université Libre de Bruxelles, Brussels, Belgium

2. **Simone Garcovich**, Università Cattolica del Sacro Cuore, Rome, Italy

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Georgios Nikolakis (georgios.nikolakis@mhb-fontane.de)

Author roles: **Nikolakis G:** Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Kreibich K:** Investigation, Methodology, Resources, Writing – Review & Editing; **Vaiopoulos A:** Supervision, Validation, Visualization, Writing – Review & Editing; **Kaletka K:** Investigation, Methodology, Supervision, Validation, Writing – Review & Editing; **Talas J:** Conceptualization, Investigation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Becker M:** Validation, Visualization, Writing – Review & Editing; **Zouboulis CC:** Conceptualization, Methodology, Project Administration, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2021 Nikolakis G *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Nikolakis G, Kreibich K, Vaiopoulos A *et al.* **Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 1; peer review: 1 approved, 1 approved with reservations]** F1000Research 2021, 10:381 <https://doi.org/10.12688/f1000research.52100.1>

First published: 13 May 2021, 10:381 <https://doi.org/10.12688/f1000research.52100.1>

Introduction

Hidradenitis suppurativa (HS) is a chronic, debilitating inflammatory skin disorder of the terminal hair follicle characterized by the presence of nodules, abscesses, tunnels and extensive scarring in the apocrine gland-rich areas of the body.¹ Immune dysregulation has been implicated in HS, with a wide range of cytokines identified. Significant increase of proinflammatory cytokines IL-1 β , TNF- α , IL-17 and the antiinflammatory cytokine IL-10 has been detected in lesional and perilesional skin.^{2,3} Apart from sporadic cases, there is a genetic background for certain HS patients, correlating with mutations in the γ -secretase genes nicastrin, presenilin enhancer 2 and presenilin.⁴ HS has been described in association with several clinical syndromes that include comorbid disorders, such as pyogenic arthritis (PA), pyoderma gangrenosum (PG), acne, ulcerative colitis (UC) and psoriatic arthritis. Such syndromes include the triad of PG, acne and HS (PASH) alone or in combination with PA (PAPASH) or psoriatic arthritis (PsAPASH). In addition, HS can also be a feature of other syndromes such as the SAPHO syndrome,⁵ which appear recalcitrant to treatment, even after the use of various biologics, such as anti-TNF and anti-IL-1. Here we describe a patient with a novel phenotypic variant of the syndromes described, who responded to treatment with the IL-17A inhibitor secukinumab.

Case

A 50-year-old female, Caucasian, unemployed patient was admitted to our departments suffering from HS. The patient reported a disease onset of 25 years, describing exacerbations with relapsing nodules, abscesses, and draining sinus tracts. Among the risk factors correlated with the disease, the patient was obese (BMI = 36) and a smoker (34-pack years). Moreover, she had a positive familial history, with her maternal grandmother having had severe refractory HS. Sequencing of the γ -secretase gene complex did not reveal any relevant mutations. The patient reported to having up to 10-15 stools daily. A colonoscopy was performed three years ago, which excluded inflammatory bowel disease. Twelve years after being diagnosed with HS, the patient developed acne conglobata (AC), which was treated without systemic therapy. In addition, she underwent numerous incisions and radical excisions, antibiotic treatment with doxycycline, and the combination of clindamycin and rifampicin over 3 months, according to the HS treatment guidelines,^{1,2} without sustained remission of the lesions. A previous 1-year therapy with isotretinoin did not improve the HS lesions. The patient was included in a clinical trial combining weekly administration of 40 mg adalimumab s.c. vs. placebo for 3 months, followed by continuation of adalimumab treatment in the same dose over 15 months. After this period, the patient was lost to follow-up. She described an improvement of the HS lesions and reduction of flares under adalimumab. During this time, her general practitioner discontinued adalimumab treatment, judging that the treatment lacked efficacy.

One month after discontinuation of adalimumab, the patient developed confluent erythematous pustules on the palms (Figure 1a) and soles (Figure 1h) with psoriasis-like scaling of the lesions followed by intermittent shoulders and knee pain and swelling. We performed a bone scan, which showed intense radiopharmaceutical accumulation of the left knee (Figure 2a) and the wrist joints showed signs of arthritis and synovitis (Figure 2b), with no typical pattern of psoriatic arthritis. The pattern of the bull's head sign (Figure 2a, red arrow) was detected. The patient did not admit having a pain or recurrent swelling of the costoclavicular region. No typical signs of osteitis were detected. Dermatohistology of the palmoplantar lesions revealed characteristic neutrophilic abscesses, compatible with pustular psoriasis (Figure 2c).

Two months after therapy discontinuation, single, disseminated, painful pustules appeared on both thighs and lower legs (Figure 1e), which progressed to painful ulcers (Figure 1f) with elevated violaceous margins. The histopathological evaluation confirmed a PG (Figure 2d). Based on the disease pathophysiology, we initiated therapy with secukinumab 300 mg s.c weekly for the first month and then monthly thereafter. Four months later, the patient demonstrated a significant remission of her HS lesions (Figure 1d) (Δ IHS4 9 and Δ DLQI 11), joint pains and pustular psoriasis (Figure 1b, Figure 1i), with only moderate improvement of her PG lesions. An epithelization was not observed. The PG showed no improvement and 100 mg prednisolone daily i.v. over three days was added to the treatment, which was subsequently tapered over one month. The treatment was followed by PG improvement (Figure 1g).

Discussion

HS can also be a main or secondary element of certain syndromes highlighted through their unique phenotypes,⁵ known as autoinflammatory diseases (AID). AID manifests with recurrent sterile inflammation, while high autoantibody serum levels or antigen-specific lymphocytes are lacking.⁶⁻⁹ These syndromes combine dermatological manifestations (HS, PPP, AC, PG), musculoskeletal disorders (arthritis, synovitis, hyperostosis, osteitis) and gastroenterological manifestations (ulcerative colitis, M. Crohn). Combinations lead to already described syndromes such as PASH,^{10,11} PASS,⁸ PAPASH,¹⁰ PsAPASH¹² and SAPHO.¹³ These disorders are characterized by aberrant release of IL-1 β , which mediates the increase of tumor necrosis factor α (TNF- α), interferon γ (IFN- γ) and other chemokines, which are responsible for neutrophilic recruitment and might promote an anti-apoptotic microenvironment.¹⁴⁻¹⁷ IL-17 also promotes neutrophilic recruitment and activation and has a synergistic effect with TNF- α .¹⁸ An imbalance of the Th17/Treg lymphocyte ratio is believed to aggravate autoinflammation and was reported both in PG and HS independently.^{19,20}

Figure 1. palmar psoriasis before (1a) and after (1b) treatment with secukinumab over 4 months. Manifestations of HS localized in the inguinofemoral region before (1c) and after (1d) treatment. Pyoderma gangrenosum two months after adalimumab discontinuation (1e), clinical image 4 months after secukinumab treatment (1f) and post-prednisolone i.v pulse therapy (1g). Plantar pustulosis before (1h) and after secukinumab treatment (1i).

Figure 2. Bone scan revealing a “bull’s head” sign-like radiopharmaceutical accumulation of the costoclavicular region (2a, red arrow) and of the wrist joints (2b). (2c): histopathologic evaluation of palmar pustular eruptions revealed characteristic microabscesses of subcorneal neutrophilic accumulation. (2d): Histology of the lower-leg ulcerations demonstrated diffuse neutrophilic inflammation as a hallmark of pyoderma gangrenosum.

We describe a new syndromic HS-related phenotype (pustular Psoriasis, Arthritis, PG, Synovitis, Acne, Suppurative Hidradenitis). The pathophysiology based on the dysregulation of IL-17 production provided the rationale for the treatment with the IL-17A inhibitor secukinumab. Moreover, this case underlines the role of the dermatologist in diagnosing such symptoms and leading a multidisciplinary approach for these patients. Dermatological manifestations can precede the osteoarticular or other organ symptoms and timely treatment initiation might avoid irreversible complications.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Consent

The patient has provided written consent for the use of all photos provided in the manuscript. The consent included potential use of the material in lecture(s) and/or publication(s).

References

1. Zouboulis CC, Desai N, Emtestam L, *et al.*: **European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa.** *J Eur*

Acad Dermatology Venereol. 2015; **29**(4): 619–44.
[PubMed Abstract](#) | [Publisher Full Text](#)

2. Zouboulis CC, Bechara FG, Fritz K, *et al.*: **S1-Leitlinie zur Therapie der Hidradenitis suppurativa/Acne inversa * (ICD-10 Ziffer: L73.2).** *JDDG - J Ger Soc Dermatol.* 2012; **10**(SUPPL. 5).
[PubMed Abstract](#) | [Publisher Full Text](#)
3. Kurzen H, Kurokawa I, Jemec GBE, *et al.*: **What causes hidradenitis suppurativa?** *Exp Dermatol.* 2008; **17**(5): 455–6.
4. Zouboulis CC, Tzellos T, Kyrgidis A, *et al.*: **Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity.** *Br J Dermatol.* 2017 Nov; **177**(5): 1401–9.
[PubMed Abstract](#) | [Publisher Full Text](#)
5. Gasparic J, Theut Riis P, Jemec GB: **Recognizing syndromic hidradenitis suppurativa: a review of the literature.** *J Eur Acad Dermatology Venereol.* 2017 Nov; **31**(11): 1809–16.
[PubMed Abstract](#) | [Publisher Full Text](#)
6. McDermott MF, Aksentjevich I, Galon J, *et al.*: **Germline mutations in the extracellular domains of the 55 kDa TNF receptor, TNFR1, define a family of dominantly inherited autoinflammatory syndromes.** *Cell.* 1999 Apr; **97**(1): 133–44.
[PubMed Abstract](#) | [Publisher Full Text](#)
7. Ciccarelli F, Martinis M, Ginaldi L: **An Update on Autoinflammatory Diseases.** *Curr Med Chem.* 2013 Dec; **21**(3): 261–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
8. Leuenberger M, Berner J, Di Lucca J, *et al.*: **PASS Syndrome: An IL-1-Driven Autoinflammatory Disease.** *Dermatology.* 2016 Apr; **232**(2): 254–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
9. Contassot E, Beer HD, French LE: **Interleukin-1, inflammasomes, autoinflammation and the skin.** *Swiss Med Wkly.* 2012 May; **142**(MAY): w13590.
[PubMed Abstract](#) | [Publisher Full Text](#)
10. Sonbol H, Duchatelet S, Miskinyte S, *et al.*: **PASH syndrome (pyoderma gangrenosum, acne and hidradenitis suppurativa): a disease with genetic heterogeneity.** *Br J Dermatol.* 2018; **178**(1): e17–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
11. Braun-Falco M, Kovnerysty O, Lohse P, *et al.*: **Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome.** *J Am Acad Dermatol.* 2012 Mar; **66**(3): 409–15.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Saraceno R, Babino G, Chiricozzi A, *et al.*: **A new syndrome associated with hidradenitis suppurativa with response to tumor necrosis factor inhibition.** *J Am. Dermatol.* 2015; **72**: e42–4.
[PubMed Abstract](#) | [Publisher Full Text](#)
13. Chamot AM, Benhamou CL, Kahn MF, *et al.*: **Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases.** *Rev Rhum Mal Osteoartic.* 1987; **54**(3): 187–96.
[PubMed Abstract](#)
14. Marzano AV, Fanoni D, Antiga E, *et al.*: **Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome.** *Clin Exp Immunol.* 2014 Oct; **178**(1): 48–56.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. Mankan AK, Dau T, Jenne D, *et al.*: **The NLRP3/ASC/Caspase-1 axis regulates IL-1 β processing in neutrophils.** *Eur J Immunol.* 2012 Mar; **42**(3): 710–5.
[PubMed Abstract](#) | [Publisher Full Text](#)
16. Guma M, Ronacher L, Liu-Bryan R, *et al.*: **Caspase 1-independent activation of interleukin-1 β in neutrophil-predominant inflammation.** *Arthritis Rheum.* 2009 Dec; **60**(12): 3642–50.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
17. Mitroulis I, Kourtzelis I, Kambas K, *et al.*: **Regulation of the autophagic machinery in human neutrophils.** *Eur J Immunol.* 2010 May; **40**(5): 1461–72.
[PubMed Abstract](#) | [Publisher Full Text](#)
18. Donetti E, Cornaghi L, Gualerzi A, *et al.*: **An innovative three-dimensional model of normal human skin to study the proinflammatory psoriatic effects of tumor necrosis factor-alpha and interleukin-17.** *Cytokine.* 2014 Jul; **68**(1): 1–8.
[PubMed Abstract](#) | [Publisher Full Text](#)
19. Moran B, Sweeney CM, Hughes R, *et al.*: **Hidradenitis Suppurativa Is Characterized by Dysregulation of the Th17:Treg Cell Axis, Which Is Corrected by Anti-TNF Therapy.** *J Invest Dermatol.* 2017 Nov; **137**(11): 2389–95.
[PubMed Abstract](#) | [Publisher Full Text](#)
20. Negus D, Ahn C, Huang W: **An update on the pathogenesis of hidradenitis suppurativa: implications for therapy.** *Expert Rev Clin Immunol.* 2018 Apr; **14**(4): 275–83.
[PubMed Abstract](#) | [Publisher Full Text](#)

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 07 June 2021

<https://doi.org/10.5256/f1000research.55330.r85308>

© 2021 Garcovich S. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Simone Garcovich

Department of Dermatology, Università Cattolica del Sacro Cuore, Rome, Italy

This is a very interesting report on a exemplary case of syndromic hidradenitis suppurativa, requiring a complex systemic treatment. While potentially interesting, there are some minor points to be addressed by the authors, to further improve an already well-written case report:

1. Regarding joint manifestations: it seems there is some minor uptake of radiotracer localized to the sacroiliac joints. Osteoarticular involvement strongly reminds the SAPHO pattern. Did the patient refer any back pain? Differential diagnosis with SAPHO should be discussed by the authors.
2. The authors propose a novel acronym for the reported case. In my opinion, the conclusion section should be more conservative, as there is no experimental (genetic, molecular, cytokine data etc.) supporting this concept. Furthermore, this is a heavily pre-treated patient with a long disease history of HS. Could there be an association between the previous exposure to multiple drugs (retinoids, anti-TNFs, etc.) and the development of "paradoxical" autoinflammatory extracutaneous involvement (such as recalcitrant PG)? This could be a more interesting take on the case? Please include some additional references.
3. Treatment: the authors should better describe the take-home messages for the therapeutic management of such complex/severe disease phenotypes. Maybe, a combination treatment strategy for complex autoinflammatory disease phenotypes is more effective than monotherapy (i.e. secukinumab alone)?

Please include some additional references on this such as:

- Garcovich *et al.* (2017)¹.
- Jin *et al.* (2019)².
- Tan *et al.* (2021)³.

References

1. Garcovich S, De Simone C, Berti E, Marzano AV: Drug management of neutrophilic dermatoses. *Expert Rev Clin Pharmacol*. 2017; **10** (10): 1119-1128 [PubMed Abstract](#) | [Publisher Full Text](#)
2. Jin K, Matsuzaki Y, Akasaka E, Nakano H, et al.: Pyoderma gangrenosum triggered by switching from adalimumab to secukinumab. *J Dermatol*. 2019; **46** (3): e108-e109 [PubMed Abstract](#) | [Publisher Full Text](#)
3. Tan Y, Kavaklieva S, Wood F: Pyoderma gangrenosum induced by biosimilar adalimumab in a seropositive rheumatoid arthritis patient - a paradoxical effect of adalimumab?. *Rheumatology (Oxford)*. 2021. [PubMed Abstract](#) | [Publisher Full Text](#)

Is the background of the case's history and progression described in sufficient detail?

Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Yes

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Partly

Is the case presented with sufficient detail to be useful for other practitioners?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Hidradenitis suppurativa

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 11 Jun 2021

Nikolakis Georgios,

We would like to thank Dr. Garcovich for approving our manuscript, their careful evaluation of the case and their contribution to its improvement.

The important differential diagnosis of the case being a variant of SAPHO syndrome including HS and a paradoxical reaction to the switch of the biologic(s) or to the previous adalimumab treatment were also addressed. An extensive opinion on combination of treatments (IL17/TNF α) or IL-1 β was included but because of the lack of controlled studies - as Dr Garcovich mentioned in their article - it cannot have a strong recommendation level.

Competing Interests: No competing interests

Reviewer Report 26 May 2021

<https://doi.org/10.5256/f1000research.55330.r85309>

© 2021 Daxhelet M. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mathilde Daxhelet

Department of Dermatology, Erasme Hospital, Université Libre de Bruxelles, Brussels, Belgium

Thank you for giving me the opportunity to review this really interesting case.

This case report describes an mixed syndrome encountered in a patient initially suffering from HS and treated with secukinumab.

The clinical, scintigraphic and histopathological images provided are of high quality.

However I would like to add some details to the case description:

- The locations of the HS lesions on the patient's skin.
- Why is she unemployed? Because of HS?
- I would also add the initial severity assessment scores (IHS4 and DLQI) before secukinumab to better understand the improvement of symptoms with treatment.
- I would specify that the bull's head sign is typical of SAPHO syndrome to facilitate understanding of the case as not all doctors are experts in interpreting bone scans.

Finally, I would add to the discussion that the initial response to secukinumab is promising but long-term follow-up of the patient is needed to assess long-term remission.

Is the background of the case's history and progression described in sufficient detail?

Partly

Are enough details provided of any physical examination and diagnostic tests, treatment given and outcomes?

Partly

Is sufficient discussion included of the importance of the findings and their relevance to future understanding of disease processes, diagnosis or treatment?

Partly

Is the case presented with sufficient detail to be useful for other practitioners?

Partly

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Hidradenitis Suppurativa

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 11 Jun 2021

Nikolakis Georgios,

We would like to thank Dr. Daxhelet for their comments and their valuable contribution to improve the manuscript

We have mentioned the initial HS scores. Unemployment was not correlated with HS. The localization of the lesions was highlighted. We added the comment about the bull's head sign and its correlation with SAPHO syndrome. A sentence was added in the discussion, underlining the importance of long-term follow-up also in combination with the other reviewer's remarks

Competing Interests: no competing interests

The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com

F1000Research